WENDY TOWNLEY: Open Payments
NPI 1730507591 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,657 in 18 payments from 13 companies in 2025. Trend: 2023 $842 · 2024 $850 · 2025 $1,657
Food & beverage: $1,657
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $250 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $230 |
| Axsome Therapeutics, Inc. | 3 | $182 |
| Novo Nordisk Inc | 2 | $148 |
| KYOWA KIRIN, INC. | 1 | $130 |
| Amgen Inc. | 1 | $129 |
| Lilly USA, LLC | 1 | $125 |
| Ardelyx, Inc. | 1 | $124 |
| AstraZeneca Pharmaceuticals LP | 1 | $121 |
| PFIZER INC. | 1 | $94 |
Products named: VRAYLAR, XIFAXAN, Auvelity, REPATHA, Ozempic, MOUNJARO, IBSRELA, AIRSUPRA.
Industry payments across LA — which companies pay providers there.
